iTeos Therapeutics (ITOS) AI Stock Analysis

• Market Cap: $386.95M
• Dividend Yield: N/A
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: N/A
• EPS Growth: 14.60%
• Country: US
• Employees: 173
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.81
• Shares Outstanding: 38,273,796
• 10 Day Avg. Volume: 1,027,833
• 30 Day Avg. Volume: 1,285,187
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: -2.17
• Enterprise Value/Gross Profit: -2.19
• Enterprise Value/Ebitda: 0.51
• 1Y Price Target: $10.21
• Price Target Upside: 1.09% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 49 Neutral
• Price Target: $10.00 ▼(-0.99% Downside)

iTeos Therapeutics' overall stock score is driven by serious financial and valuation concerns, despite a favorable technical position and potential benefits from corporate events. The merger announcement offers some optimism, but strategic challenges and negative financials weigh heavily.

Positive Factors

Acquisition

The acquisition by Concentra Biosciences is likely to close with the top two shareholders, EcoR1 and Tang Capital, in a positive position.

Cash Position

ITeos ended 1Q:25 with cash of $624 million, indicating a strong cash position before the acquisition.

Strategic Review

Investors reacted positively to the news of belrestotug’s termination, with the stock showing an increase, likely due to the announcement of a strategic review to maximize shareholder value.

Negative Factors

Legal Risks

The deal lacks a provision for shareholder vote, which may lead to legal disputes similar to other Concentra deals.

Pipeline Development

There is low confidence that any early-stage immuno-oncology asset will add value for iTeos in the next year, as the investor bar for excitement is high.

Shareholder Expectations

The terms of the acquisition may not meet broader shareholder expectations, being approximately 30% to previously disclosed iTeos cash.

iTeos Therapeutics Business Overview & Revenue Model

Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

iTeos Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model is primarily based on partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of successfully developed therapies. Additionally, iTeos may receive revenue from grants and research funding. Key revenue streams include strategic alliances with industry leaders, which enable the company to leverage external resources and expertise to advance its drug candidates through the clinical trial phases and towards regulatory approval.

iTeos Therapeutics Financial Statement Overview

Summary

iTeos Therapeutics faces significant financial challenges with declining profitability, negative cash flows, and reliance on external financing. Despite a strong equity base, the overall financial health is concerning and needs improvement in revenue generation and cost management.

Income Statement

iTeos Therapeutics has experienced significant volatility in its revenue and profitability. The TTM (Trailing-Twelve-Months) data shows a severe decline in profitability, with negative EBIT and net income margins. Revenue growth is stagnant, as current revenue matches the previous period. These trends reflect challenges in generating consistent revenue and managing costs, which is critical for long-term sustainability.

Balance Sheet

The balance sheet reveals a strong equity base, with a high equity ratio indicating stability. However, the debt-to-equity ratio is low, which is positive, though offset by declining total assets and stockholders' equity over recent periods. Despite these strengths, the decrease in cash reserves and equity suggests potential challenges in maintaining financial health if current trends continue.

Cash Flow

The cash flow situation is concerning with negative operating and free cash flows, indicating struggles in generating cash from operations. The free cash flow growth rate is negative, highlighting a worsening trend. Despite a positive financing cash flow, reliance on external funding is not a sustainable strategy for cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.00M	12.60M	267.63M	344.77M	0.00
Gross Profit	33.76M	11.70M	266.82M	344.16M	-535.00K
EBITDA	-159.53M	-151.10M	148.38M	257.08M	-37.84M
Net Income	-134.41M	-112.64M	96.65M	214.52M	-38.03M
Balance Sheet
Total Assets	686.98M	667.59M	754.99M	884.71M	344.56M
Cash, Cash Equivalents and Short-Term Investments	494.65M	531.92M	613.16M	848.54M	336.33M
Total Debt	5.10M	6.06M	4.67M	5.34M	0.00
Total Liabilities	96.68M	92.36M	91.66M	331.89M	21.36M
Stockholders Equity	590.29M	575.23M	663.33M	552.82M	323.20M
Cash Flow
Free Cash Flow	-99.81M	-106.72M	-112.13M	511.96M	-25.53M
Operating Cash Flow	-98.18M	-103.76M	-111.19M	513.14M	-25.18M
Investing Cash Flow	-131.15M	72.66M	-446.06M	-1.24M	-377.00K
Financing Cash Flow	122.24M	1.11M	1.98M	3.66M	340.34M

iTeos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITOS, the sentiment is Neutral. The current price of 10.1 is below the 20-day moving average (MA) of 10.18, above the 50-day MA of 10.02, and above the 200-day MA of 8.19, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 53.08 is Neutral, neither overbought nor oversold. The STOCH value of 8.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ITOS.

iTeos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$405.17M	―	-41.31%	―	―	-7.93%
Sector *	60 Neutral	HK$17.57B	4.99	-4.95%	3.61%	9.71%	-38.85%
ITOS	49 Neutral	$386.95M	―	-34.97%	―	―	14.60%
ABSI	49 Neutral	$425.48M	―	-48.98%	―	-9.95%	20.78%
BCAX	48 Neutral	$569.36M	―	34.94%	―	―	―
MBX	38 Underperform	$399.42M	―	-48.22%	―	―	―
GOSS	35 Underperform	$490.97M	―	-783.37%	―	―	81.94%

iTeos Therapeutics Corporate Events

iTeos Therapeutics Announces Merger with Concentra Biosciences

On July 18, 2025, iTeos Therapeutics entered into a merger agreement with Concentra Biosciences, where Concentra will acquire iTeos for $10.047 in cash per share plus a contingent value right. The iTeos board has unanimously approved the merger, which is expected to close in the third quarter of 2025, subject to certain conditions including a minimum cash requirement and shareholder approval. This acquisition is seen as beneficial for iTeos’ stockholders and aligns with the company’s strategic goals.

The most recent analyst rating on (ITOS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.

iTeos Therapeutics Holds Annual Stockholders Meeting

iTeos Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2025, with a quorum of 87.67% of outstanding shares present or represented by proxy. During the meeting, stockholders elected Tony Ho, Robert Iannone, and Ann D. Rhoades as Class II directors for a three-year term and ratified Deloitte Bedrijfsrevisoren / Réviseurs d’Entreprises BV/SRL as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ITOS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.

Tim Van Hauwermeiren Resigns from iTeos Board

On June 1, 2025, Tim Van Hauwermeiren resigned from the Board of Directors of iTeos Therapeutics, Inc., effective immediately. His resignation was not due to any disagreements with the company, its management, or the board, indicating a smooth transition without internal conflict.

The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.

iTeos Therapeutics Announces Strategic Wind Down Plan

On May 28, 2025, iTeos Therapeutics announced its plan to wind down its clinical and operational activities as part of a strategic review to maximize shareholder value. This decision follows the termination of its belrestotug development program and collaboration with GlaxoSmithKline, leading to expected charges related to severance, contract terminations, and winding down costs. The company will focus on leveraging its cash balance and exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, to deliver near-term value to shareholders.

The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.

iTeos Therapeutics Ends Collaboration with GSK

On May 13, 2025, iTeos Therapeutics and GlaxoSmithKline (GSK) announced the termination of their collaboration and license agreement, originally established in June 2021, following interim results from the GALAXIES Lung-201 study. The study, which assessed the combination of belrestotug and dostarlimab in non-small cell lung cancer, did not meet the criteria for progression-free survival improvements, leading to the decision to end the belrestotug development program. This termination will result in the cessation of financial obligations between the two companies and the end of new enrollment in ongoing trials. iTeos plans to explore strategic alternatives to maximize shareholder value, despite the disappointing trial results.

The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.